Lung Function Improvement After Bronchoscopic Lung Volume Reduction With Pulmonx Endobronchial Valves Used in Treatment of Emphysema
The Pulmonx Zephyr Endobronchial Valve (EBV) is an implantable bronchial valve intended to
decrease volume in targeted regions of the lung. It is indicated for the treatment of
patients with severe emphysema. The EBV are placed in the diseased region of the lung using
bronchoscopy. Bronchoscopy is a way to access the lungs using a small tube with a camera on
the end. As the diseased region of the lung shrinks in size, healthier regions may expand
and function more efficiently, resulting in improved breathing.
The LIBERATE Study is a clinical trial with two groups. Participants are assigned at random
to the 'Treatment' group or to the 'Control' group. The 'Treatment' group will receive the
Zephyr Endobronchial Valve (EBV) in combination with optimal medical therapy. The 'Control'
group will receive optimal medical therapy alone. For every three participants in the study,
two will go into the 'Treatment' group and one will go into the 'Control' group.
It is hypothesized that after placement of the EBV, lung function will be improved as
compared to standard medical therapy alone.
Powered by
SC CTSI